var data={"title":"Fluticasone (nasal): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluticasone (nasal): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7784?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluticasone-nasal-drug-information\" class=\"drug drug_general\">see &quot;Fluticasone (nasal): Drug information&quot;</a> and <a href=\"topic.htm?path=fluticasone-nasal-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluticasone (nasal): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349460\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Flonase Allergy Relief [OTC];</li>\n      <li>Flonase Sensimist [OTC];</li>\n      <li>Flonase [DSC];</li>\n      <li>GoodSense Nasoflow [OTC];</li>\n      <li>Ticaspray;</li>\n      <li>Veramyst [DSC];</li>\n      <li>Xhance</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349461\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Avamys;</li>\n      <li>Flonase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F990162\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Intranasal</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F990173\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fluticasone-nasal-drug-information\" class=\"drug drug_general\">see &quot;Fluticasone (nasal): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Product formulations are not interchangeable: Flonase: One spray delivers 50 mcg/spray; Veramyst: One spray delivers 27.5 mcg/spray </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinitis, nonallergic:</b> Flonase (fluticasone propionate, 50 mcg/spray): Children &ge;4 years and Adolescents: Initial: 1 spray <b>per nostril</b> once daily (total daily dose: 100 mcg/day). If response is inadequate, increase to 2 sprays <b>per nostril</b> once daily (total daily dose: 200 mcg/day). Once symptoms are controlled, reduce dose to 1 spray <b>per nostril</b> once daily (total daily dose: 100 mcg/day). Maximum dose: 2 sprays (100 mcg) <b>per nostril</b> (total dose: 200 mcg). <b>Note:</b> For optimal effects, nasal spray should be used at regular intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinitis, allergic (seasonal and perennial):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flonase OTC (fluticasone propionate, 50 mcg/spray) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 4 to 11 years: 1 spray <b>per nostril</b> once daily (total daily dose: 100 mcg/day). Do not use for more than 2 months unless instructed by health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Initial: 2 sprays <b>per nostril</b> once daily (total daily dose: 200 mcg/day) for 1 week; then may adjust to 1 or 2 sprays <b>per nostril</b> once daily (total daily dose range: 100 to 200 mcg/day). Do not use for more than 6 months unless instructed by health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Veramyst (fluticasone furoate, 27.5 mcg/spray): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to 11 years: Initial: 1 spray <b>per nostril</b> once daily (total daily dose: 55 mcg/day); if response is inadequate, increase to 2 sprays <b>per nostril</b> once daily (total daily dose: 110 mcg/day); once symptoms have been controlled, the dosage may be reduced to 1 spray <b>per nostril</b> once daily (total daily dose: 55 mcg/day). Maximum dose: 2 sprays <b>per nostril</b>/day (total daily dose: 110 mcg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Initial: 2 sprays <b>per nostril</b> once daily (total daily dose: 110 mcg/day); once symptoms are controlled, dosage may be reduced to 1 spray <b>per nostril</b> once daily (total daily dose: 55 mcg/day) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Rhinitis:</b> Intranasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flonase (fluticasone propionate, 50 mcg/spray): Initial: 2 sprays <b>per nostril</b> once daily (200 mcg/day); alternatively, the same total daily dosage may be divided and given as 1 spray <b>per nostril</b> twice daily (200 mcg/day). After the first few days, dosage may be reduced to 1 spray <b>per nostril</b> once daily for maintenance therapy (100 mcg/day). Maximum dose: 2 sprays <b>per nostril</b>/day (200 mcg/day). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flonase OTC (fluticasone propionate, 50 mcg/spray): Initial: 2 sprays <b>per nostril</b> once daily (200 mcg/day); after 1 week, may adjust to 1 or 2 sprays <b>per nostril</b> once daily (100 to 200 mcg/day). Do not use for more than 6 months unless instructed by health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Veramyst (fluticasone furoate): Initial: 2 sprays <b>per nostril</b> once daily (110 mcg/day); once symptoms are controlled, may reduce dosage to 1 spray <b>per nostril</b> once daily (55 mcg/day) for maintenance therapy. Maximum dose: 2 sprays <b>per nostril</b>/day (110 mcg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; has not been studied. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Use with caution in patients with severe hepatic impairment; systemic availability of fluticasone may be increased in patients with hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242539\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Exhaler Suspension, Nasal, as propionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xhance: 93 mcg/actuation (16 mL) [contains benzalkonium chloride, edetate disodium dihydrate, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Nasal, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flonase Sensimist: 27.5 mcg/spray (5.9 mL, 9.1 mL, 9.9 mL, 15.8 mL) [contains benzalkonium chloride, edetate disodium, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Veramyst: 27.5 mcg/spray (10 g [DSC]) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Nasal, as propionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flonase: 50 mcg/actuation (16 g [DSC]) [contains benzalkonium chloride, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flonase Allergy Relief: 50 mcg/actuation (9.9 mL, 15.8 mL, 18.2 mL) [contains benzalkonium chloride, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Nasoflow: 50 mcg/actuation (15.8 mL) [contains alcohol, usp, benzalkonium chloride, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mcg/actuation (16 g, 9.9 mL, 15.8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Therapy Pack, Nasal, as propionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ticaspray: 50 mcg/actuation (1 ea) [contains benzalkonium chloride, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349463\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005929\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=fluticasone-nasal-drug-information\" class=\"drug drug_general\">see &quot;Fluticasone (nasal): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flonase 16 g bottles and Veramyst 10 g bottles contain 120 sprays each.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flonase Allergy Relief 9.9 mL bottles contain 60 sprays, and the 15.8 mL bottles contain 120 sprays.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50617005\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Xhance (fluticasone propionate) nasal spray: FDA approved September 2017; availability anticipated in the second quarter of 2018.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F990174\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Shake well prior to each use. Blow nose to clear nostrils before each use. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Do not spray into eyes. Discard after labeled number of doses has been used, even if bottle is not completely empty. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Flonase&reg;: Prime pump (press 6 times until fine spray appears) prior to first use or if spray unused for &ge;7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Veramyst&reg;: Prime pump (press 6 times until fine spray appears) prior to first use, if spray unused for &gt;30 days, or if cap left off bottle for &ge;5 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349526\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ClariSpray, Flonase, Flonase Allergy Relief, Good Sense Nasoflow: Store between 4&deg;C to 30&deg;C (39&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Veramyst, Flonase Sensimist: Store between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not refrigerate or freeze. Store Veramyst in upright position with cap on.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xhance: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Avoid exposure to extreme heat, cold, or light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avamys [Canadian product]: Store between 4&deg;C to 30&deg;C (39&deg;F to 86&deg;F); do not refrigerate or freeze. Store in upright position with cap on.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F990163\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Flonase: Management of nasal symptoms associated with nonallergic rhinitis (FDA approved in ages &ge;4 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Veramyst: Management of nasal symptoms associated with seasonal and perennial allergic rhinitis (FDA approved in ages &ge;2 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">OTC labeling: Relief of hay fever or other upper respiratory allergies (eg, nasal congestion, runny nose, sneezing, itchy nose) (FDA approved in ages &ge;4 years and adults)</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Intranasal corticosteroids have also been used as an adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis primarily in patients with history of allergic rhinitis (Chow 2012) and in pediatric patients with mild obstructive sleep apnea syndrome who cannot undergo adenotonsillectomy or who still have symptoms after surgery (Marcus 2012). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349456\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flonase may be confused with Flovent</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allegro: Brand name for fluticasone [Israel], but also the brand name for frovatriptan [Germany] </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allegro [Israel] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoephedrine, respectively, [US, Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349492\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Body pain, dizziness, generalized ache, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, abdominal pain, diarrhea, nausea and vomiting, toothache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation (nose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Increased intraocular pressure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Acute asthma, acute sinusitis, blood in nasal mucosa, bronchitis, cough, dry nose, epistaxis, flu-like symptoms, nasal congestion, nasal mucosa ulcer (includes nasal septal ulceration), nasopharyngitis, oropharyngeal pain, pharyngitis, rhinorrhea, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Altered sense of smell, anaphylactoid reaction, anaphylaxis, angioedema, blurred vision, bronchospasm, cataract, conjunctivitis, contact dermatitis, dry eye syndrome, dry throat, dysgeusia, dyspnea, esophageal candidiasis, eye irritation, facial edema, glaucoma, growth suppression, hoarseness, hypersensitivity reaction, intestinal candidiasis, nasal candidiasis, nasal septum perforation, pharyngeal candidiasis, pruritus, skin rash, sore throat, throat irritation, tongue edema, urticaria, voice disorder, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242544\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fluticasone or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use in children &lt;4 years of age (Clarispray, Flonase Allergy Relief, Good Sense Nasoflow) or children &lt;2 years of age (Flonase Sensimist), for the treatment of asthma, or with current injury or surgery to nose that is not fully healed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for intranasal steroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Flonase: Untreated fungal, bacterial, or tuberculosis infections of the respiratory tract</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242529\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Pediatric patients may be more susceptible to systemic toxicity. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &ge;20 mg per day of prednisone (or equivalent) may be most susceptible. Concurrent use of ritonavir (and potentially other strong inhibitors of CYP3A4) may increase fluticasone levels and effects on HPA suppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delayed wound healing: Avoid use in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healing has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including anaphylaxis, angioedema, rash, contact dermatitis, hypotension, bronchospasm, and urticaria) have been reported; discontinue for severe reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox and/or measles should be avoided, especially if not immunized; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intramuscular immunoglobulin, respectively, may be indicated; if chickenpox develops, treatment with antiviral agents may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local nasal effects: Nasal septal perforation, nasal ulceration, nasal erosion, epistaxis, and localized <i>Candida albicans</i> infections of the nose and/or pharynx may occur. Monitor patients periodically for adverse nasal effects; discontinuation of therapy may be necessary if an infection occurs; discontinue therapy if nasal septal perforation occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment (accumulation may occur); monitor patients closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Use caution or avoid use in patients with active or quiescent tuberculosis infections of the respiratory tract, systemic fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Do not use in untreated localized infection involving the nasal mucosa; concurrent antimicrobial therapy should be administered if bacterial infection of the sinuses is suspected/confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in long-term users or in patients who report visual changes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth). Use for the shortest amount of time necessary to achieve symptom relief.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Prior to use, the dose and duration of treatment should be based on the risk vs benefit for each individual patient. In general, use the smallest effective dose for the shortest duration of time to minimize adverse events. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing inhalation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): Consult a health care provider before use if you taking medicine for HIV infection (eg, ritonavir), steroid for asthma, allergies, or skin rash, or ketoconazole (for a fungal infection). Discontinue use and consult a health care provider if you have come in contact with someone who has chicken pox, measles, or tuberculosis, symptoms do not get better within 7 days or new symptoms occur (eg, severe facial pain, thick nasal discharge), constant whistling sound from nose, changes in vision, or severe or frequent nosebleeds. Stinging or sneezing may occur for a few seconds after use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Symptoms of corticosteroid withdrawal (eg, joint pain, muscle pain, lassitude, depression) may occur when transferring from a systemic corticosteroid to a topical corticosteroid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820120\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In a small pediatric study conducted over one year, no statistically significant effect on growth velocity or clinically relevant changes in bone mineral density or HPA axis function were observed in children 3 to 9 years of age receiving fluticasone propionate nasal spray (200 mcg/day; n=56) versus placebo (n=52); effects at higher doses or in susceptible pediatric patients cannot be ruled out.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349495\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242533\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15932&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Nasal).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Nasal) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242534\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349487\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Fluticasone can be detected in cord blood following maternal use via oral inhalation during pregnancy; one woman in the study was also using intranasal fluticasone (Battista 2016). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intranasal corticosteroids, including fluticasone, may be acceptable for the treatment of rhinitis during pregnancy when used at recommended doses (Lal 2016; Wallace 2008). Pregnant females adequately controlled on fluticasone may continue therapy; if initiating treatment during pregnancy, use of an agent with more data during pregnancy may be preferred (Namazy 2016; Wallace 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21207714\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mucous membranes for signs of fungal infection, growth (pediatric patients), signs/symptoms of HPA axis suppression/adrenal insufficiency; ocular changes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242527\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fluticasone belongs to a group of corticosteroids which utilizes a fluorocarbothioate ester linkage at the 17 carbon position; extremely potent vasoconstrictive and anti-inflammatory activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242543\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Maximal benefit may take several days or several months (Xhance)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Fluticasone propionate: 4.2 L/kg; Fluticasone furoate: V<sub>d,ss</sub>: 608 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 to 17 beta-carboxylic acid (negligible activity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: &lt;2%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: Fluticasone propionate: ~8 hours (~7.8 hours [Xhance]); Fluticasone furoate: ~15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Oral: Feces (as parent drug and metabolites); Urine (&lt;5% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349541\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Exhaler Suspension</b> (Xhance Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">93 mcg/ACT (16 mL): $510.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Flonase Allergy Relief Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/ACT (9.9 mL): $14.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Flonase Sensimist Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">27.5 mcg/spray (15.8 mL): $26.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Fluticasone Propionate Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/ACT (16 g): $84.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Therapy Pack</b> (Ticaspray Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MCG/ACT 0.9% (1): $3,783.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961908\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alenys (AR);</li>\n      <li>Alisade (EE, MT);</li>\n      <li>Allegro (IL);</li>\n      <li>Allermist (JP);</li>\n      <li>Avamys (AE, AT, AU, BE, BH, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, ET, FR, GB, GR, GT, HK, HN, HR, ID, IE, IL, IS, IT, JO, KR, KW, LB, LK, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VN, ZW);</li>\n      <li>Avaspray (BD);</li>\n      <li>Clefan (MY);</li>\n      <li>Dalmam AQ (HK);</li>\n      <li>Flixonas (PK);</li>\n      <li>Flixonase (AR, AT, AU, BE, BG, BH, BR, CL, CN, CY, CZ, DK, DO, EC, EE, EG, ES, FI, FR, GB, HK, HN, HR, IE, IL, IS, IT, JM, JO, KR, KW, LB, LK, LT, LU, LV, MT, NL, NZ, PA, PE, PH, PL, PY, QA, RO, RU, SA, SG, SI, SK, SV, TH, TR, TT, TW, UY, VE, VN);</li>\n      <li>Flixonase Nasule (IL);</li>\n      <li>Flomist (MY, ZW);</li>\n      <li>Flusort (PH);</li>\n      <li>Flutaide (PT);</li>\n      <li>Flutica (BD, DE);</li>\n      <li>Fluticone (LK);</li>\n      <li>Flutide (NO, SE);</li>\n      <li>Flutinasal (GR);</li>\n      <li>Flutinase (CH);</li>\n      <li>Flutinide (MY);</li>\n      <li>Flutitrim (SG);</li>\n      <li>Lutisone (HK);</li>\n      <li>Nasofan (HK);</li>\n      <li>Nasoflo (PH);</li>\n      <li>Novex (CO);</li>\n      <li>Perinase (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Asthma Medication Use in Pregnancy and Fetal Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2005, 116(3):503-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/16159616/pubmed\" target=\"_blank\" id=\"16159616\">16159616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &quot;IDSA Clinical Practice Guideline For Acute Bacterial Rhinosinusitis in Children and Adults,&quot; <i>Clin Infect Dis</i>, 2012, 54(8):e72-e112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flonase nasal spray (fluticasone nasal) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flonase nasal spray (fluticasone nasal) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2003.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcus CL, Brooks LJ, Draper KA, et al, &quot;Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome,&quot; <i>Pediatrics</i>, 2012, 130(3):576-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/22926173/pubmed\" target=\"_blank\" id=\"22926173\">22926173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M, Long L, et al, &ldquo;Use of Inhaled Steroids by Pregnant Asthmatic Women Does Not Reduce Intrauterine Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2004, 113(3):427-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/15007341/pubmed\" target=\"_blank\" id=\"15007341\">15007341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veramyst (fluticasone nasal) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace DV, Dykewicz MS, Bernstein DI, et al, &quot;The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,&quot; <i>J Allergy Clin Immunol</i>, 2008, 122(2 Suppl):S1-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/18662584/pubmed\" target=\"_blank\" id=\"18662584\">18662584</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15932 Version 169.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9349460\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9349461\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F990162\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F990173\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F242539\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9349463\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005929\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50617005\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F990174\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9349526\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F990163\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9349456\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9349492\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F242544\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F242529\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820120\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9349495\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F242533\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F242534\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9349487\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F21207714\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F242527\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F242543\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9349541\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961908\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15932|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluticasone-nasal-drug-information\" class=\"drug drug_general\">Fluticasone (nasal): Drug information</a></li><li><a href=\"topic.htm?path=fluticasone-nasal-patient-drug-information\" class=\"drug drug_patient\">Fluticasone (nasal): Patient drug information \t</a></li></ul></div></div>","javascript":null}